Pegvisomant

Pegvisomant Market Outlook

The global Pegvisomant market is poised for significant growth, expected to reach approximately USD 1.5 billion by 2033, with a CAGR of around 8% during the forecast period from 2025 to 2033. This growth can be attributed to the increasing prevalence of acromegaly and other hormonal disorders, along with advances in biotechnology that enhance drug efficacy and delivery. The rising awareness regarding hormonal disorders and their treatment options is also contributing to market demand. Moreover, the ongoing research and development efforts aimed at introducing innovative therapies are expected to provide a further boost to the market. Collaborative efforts between pharmaceutical companies and healthcare providers are increasingly focusing on optimizing patient outcomes, thereby accelerating the growth trajectory of the Pegvisomant market.

Growth Factor of the Market

The Pegvisomant market is driven by several key factors that collectively enhance its growth potential. Firstly, the global rise in the incidence of acromegaly, a condition characterized by excess growth hormone, is a substantial contributing factor, as Pegvisomant is specifically designed to treat such hormonal imbalances. Secondly, advancements in biotechnology and pharmaceutical formulations have led to improved efficacy and safety profiles of Pegvisomant, making it a preferred choice among both healthcare providers and patients. Thirdly, the increasing investment in R&D by pharmaceutical companies is fostering the introduction of new delivery mechanisms and formulations, which are anticipated to attract a broader patient base. Furthermore, the expansion of healthcare facilities and the rising number of specialized clinics dedicated to treating hormonal disorders are facilitating greater access to Pegvisomant treatment options. Lastly, the growing online pharmacy sector is ushering in an era of convenience, allowing patients to procure their medications with ease, thereby catalyzing market growth.

Key Highlights of the Market

• The global Pegvisomant market is projected to reach USD 1.5 billion by 2033.
• North America holds the largest market share, driven by advanced healthcare infrastructure.
• Injection form of Pegvisomant dominates the product type segment due to its established effectiveness.
• Acromegaly is the leading application segment, accounting for a significant share of market revenue.
• Online pharmacies are emerging as a popular distribution channel, enhancing accessibility for patients.

By Product Type

Injection:

The injection segment of the Pegvisomant market is the most significant, accounting for a substantial share due to its proven efficacy in managing hormonal disorders, particularly acromegaly. Pegvisomant injections are generally administered subcutaneously, allowing for direct absorption into the bloodstream, which enhances the drug's effectiveness. The dosage and frequency of injections can be tailored to individual patient needs, making it a flexible treatment option. The established track record of injections in clinical practice has resulted in high patient compliance and satisfaction rates. Furthermore, ongoing innovations in injection technology, including pre-filled syringes and autoinjectors, are expected to improve patient convenience and adherence to therapy. These factors collectively contribute to the dominance of the injection form in the Pegvisomant product type segment.

Tablet:

The tablet segment, while smaller in comparison to injections, is gaining traction as an alternative delivery method for Pegvisomant. Tablets offer the advantage of oral administration, which is generally more acceptable to patients who prefer avoiding needles. The development of effective tablets requires advanced formulation techniques to ensure optimal bioavailability and steady release of the active ingredient. As pharmaceutical companies invest in research to enhance tablet formulations, it is anticipated that this segment will see an increase in popularity among patients seeking non-injection options. Additionally, the convenience of oral administration can improve patient adherence to treatment regimens, contributing to better therapeutic outcomes.

Capsule:

The capsule segment represents another oral delivery form of Pegvisomant, similar to tablets, but with certain advantages in terms of patient acceptance. Capsules can mask unpleasant tastes and can be easier to swallow compared to traditional tablets, making them particularly beneficial for pediatric patients and those with swallowing difficulties. Innovations in capsule technology, including time-release formulations, can further enhance the efficacy and patient experience. As healthcare providers strive to offer a range of options that cater to diverse patient preferences, the capsule segment is expected to grow, albeit at a slower rate compared to injections and tablets due to the historical dominance of injectable forms in treating hormonal disorders.

Liquid:

The liquid form of Pegvisomant is primarily used in specialized settings where patients may require immediate dosing adjustments or have difficulty with solid forms of medication. This segment is particularly beneficial for patients with swallowing difficulties, as it allows for flexible dosing and easy administration. However, the liquid formulation's market share is limited compared to the more established injection and oral forms. The development of liquid formulations requires meticulous attention to stability and dosage accuracy, which can pose challenges in manufacturing and distribution. Nevertheless, as healthcare providers seek to customize treatment approaches for individual patient needs, the liquid segment may see gradual growth, especially in clinical environments focused on patient-centric care.

Powder:

The powder segment of Pegvisomant is primarily used for reconstitution before administration, which provides flexibility in dosing. This form allows healthcare professionals to tailor the dosage based on specific patient needs and can be particularly valuable in hospital settings where precise dosing is critical. However, the powder form requires additional steps for preparation, which may deter some patients and healthcare providers in favor of more straightforward administration methods like injections. Despite these challenges, powder formulations can be advantageous for scalability and storage, making them relevant in contexts where bulk preparation is needed. As market dynamics evolve, the powder segment could carve out a niche for specific therapeutic applications, especially in research and clinical trials.

By Application

Acromegaly:

Acromegaly remains the leading application segment for Pegvisomant, accounting for a significant portion of the overall market. This condition, caused by excessive growth hormone production, necessitates effective management solutions to alleviate symptoms and prevent complications. Pegvisomant acts as a growth hormone receptor antagonist, effectively blocking the action of growth hormone and helping to normalize IGF-1 levels in patients. The increasing awareness of acromegaly and its long-term effects is driving demand for effective treatments. Moreover, ongoing research into the impact of Pegvisomant on quality of life for acromegaly patients is expected to boost its uptake, as healthcare providers increasingly focus on comprehensive care that addresses both medical and psychological aspects of the disorder.

Neuroendocrine Tumors:

The application of Pegvisomant in treating neuroendocrine tumors is an emerging area that holds substantial potential for market expansion. Neuroendocrine tumors originate from cells of the neuroendocrine system and can produce hormones that lead to a variety of health issues. Although Pegvisomant is primarily marketed for acromegaly, research is ongoing to understand its efficacy in managing hormone-related complications associated with neuroendocrine tumors. The encouraging results from clinical trials may pave the way for broader indications, driving interest from oncologists and leading to increased adoption of Pegvisomant for this application. As awareness grows regarding the importance of targeted therapy for neuroendocrine tumors, the market share for this application segment is expected to rise significantly.

Other Hormonal Disorders:

The segment for other hormonal disorders encompasses a range of conditions that may benefit from Pegvisomant therapy. As the understanding of hormonal imbalances evolves, healthcare professionals are exploring the use of Pegvisomant for disorders beyond its primary indication. These conditions can include various endocrine disorders that affect metabolic rates, growth, and hormonal balance. The increasing focus on personalized medicine is driving research into the applicability of Pegvisomant in treating these disorders, which may result in expanded usage and greater market penetration. Additionally, patient advocacy for improved treatment options is helping to raise awareness about the potential benefits of Pegvisomant in addressing these complex hormonal conditions.

Research:

The research application segment of the Pegvisomant market highlights its role in scientific studies aimed at understanding growth hormone-related disorders and testing new therapeutic combinations. Pegvisomant is often used in clinical trials to assess its safety and efficacy as part of broader treatment regimens. The ongoing research efforts into its mechanisms of action, dosage optimization, and potential new indications are critical for advancing the field of endocrinology. Furthermore, institutions and pharmaceutical companies are increasingly collaborating to explore innovative applications of Pegvisomant, resulting in a growing demand within this segment. As scientific inquiry continues to expand, the research application segment is likely to see an increase in investment and focus, further solidifying Pegvisomant’s position within the pharmaceutical landscape.

By Distribution Channel

Hospitals:

The hospital distribution channel is a major segment for the Pegvisomant market, as hospitals are often the primary settings for diagnosing and treating acromegaly and other hormonal disorders. In-hospital pharmacies maintain a stock of Pegvisomant to ensure immediate access for patients requiring treatment. The presence of endocrinologists and specialized medical staff within hospitals facilitates comprehensive patient management and monitoring, which is crucial for the effective use of Pegvisomant. Additionally, the availability of multidisciplinary teams in hospitals helps in managing potential side effects and tailoring treatment regimens based on individual patient responses. As hospitals continue to enhance their offerings in endocrinology care, the demand for Pegvisomant through this channel is expected to remain robust.

Retail Pharmacies:

Retail pharmacies play a significant role in the distribution of Pegvisomant, providing patients with convenient access to their medications. These pharmacies collaborate with healthcare providers to ensure that patients receive proper counseling about the use of Pegvisomant, its potential side effects, and the importance of adherence to prescribed therapies. The increasing prevalence of chronic diseases, including hormonal disorders, is driving patient visits to retail pharmacies in search of effective treatments. Additionally, retail pharmacies are investing in technology-driven solutions to streamline prescription management and improve patient engagement. As patients seek easier access to their medications, the retail pharmacy segment is expected to witness steady growth in Pegvisomant sales.

Online Pharmacies:

The rise of online pharmacies is reshaping the distribution landscape for Pegvisomant, allowing patients to procure their medications with greater convenience and privacy. The digital transformation of the healthcare sector has led to an increase in telemedicine and e-pharmacy services, making it easier for patients to access prescriptions without the need for physical visits to healthcare facilities. Online pharmacies often offer competitive pricing and home delivery options, which appeal to many patients, especially those with chronic conditions requiring long-term treatment. This segment is expected to grow rapidly, driven by advancements in e-commerce and increasing patient demand for accessible healthcare solutions. However, the online pharmacy market also necessitates strict regulatory oversight to ensure patient safety and the legitimacy of distributed medications.

Specialty Clinics:

Specialty clinics that focus on endocrine disorders are crucial distribution channels for Pegvisomant, as they provide targeted care and treatment plans tailored to individual patient needs. These clinics often house endocrinology specialists who are adept at managing complex hormonal imbalances and can offer in-depth consultations on the use of Pegvisomant. The personalized approach taken by specialty clinics enhances patient adherence to treatment, as patients receive ongoing monitoring and support throughout their therapy. The collaboration between clinics and pharmaceutical companies to streamline the procurement of Pegvisomant can lead to improved patient outcomes and satisfaction. As the prevalence of endocrine disorders continues to rise, the specialty clinic distribution channel is likely to experience significant growth.

Research Institutes:

Research institutes are significant players in the Pegvisomant market, particularly in the context of clinical trials and studies aimed at exploring new applications and dosage regimens. These institutions often collaborate with pharmaceutical companies to investigate the efficacy of Pegvisomant in various therapeutic settings, contributing to the overall knowledge base in endocrinology. The insights gained from research studies can facilitate the development of new formulations and delivery mechanisms, ultimately benefiting patient care. Furthermore, as awareness grows regarding the importance of research-driven innovations, the demand for Pegvisomant in research institutes is expected to increase. This segment plays a vital role in the continuous evolution of treatment strategies for hormonal disorders.

By Ingredient Type

Pegvisomant:

Pegvisomant, the active ingredient in the market, is a recombinant growth hormone receptor antagonist utilized for the treatment of growth hormone excess. Its unique mechanism of action inhibits the binding of growth hormone to its receptor, effectively reducing the action of growth hormones that lead to conditions like acromegaly. The pharmaceutical development of Pegvisomant has undergone rigorous testing and validation, ensuring its safety and effectiveness in clinical use. The formulation of Pegvisomant is meticulously crafted to enhance its bioavailability and minimize side effects, making it a preferred choice among endocrinologists. As research continues to unveil the broader therapeutic potentials of Pegvisomant, its ingredient type will remain central to the market, influencing formulation advancements and new therapeutic applications.

By Region

The North American Pegvisomant market is currently the largest, driven by advanced healthcare systems, high rates of hormone-related disorders, and a greater propensity for patients to seek medical help. The region is anticipated to retain its dominance through 2033 due to robust healthcare infrastructure and the presence of leading pharmaceutical companies engaged in research and development. Furthermore, North America boasts a high awareness level about hormonal disorders, leading to early diagnosis and treatment. With a CAGR of approximately 7.5%, the region is positioned for sustainable growth propelled by ongoing healthcare innovation and increasing patient access to medications.

In Europe, the Pegvisomant market is experiencing steady growth, spurred by expanding healthcare access and increasing awareness of hormonal disorders. The European market is expected to reach USD 400 million by 2033, with a CAGR of around 6% during the forecast period. The region benefits from stringent regulatory frameworks that promote safe and effective pharmaceutical practices. Additionally, collaborations between healthcare providers and pharmaceutical companies are driving research efforts aimed at optimizing Pegvisomant therapies. The rising incidence of conditions like acromegaly and the growing patient advocacy for better treatment options are also contributing factors to the positive outlook for the European Pegvisomant market.

Opportunities

The Pegvisomant market presents numerous opportunities for growth, chiefly driven by ongoing advancements in biotechnology and personalized medicine. As the understanding of hormonal disorders continues to evolve, there is an increasing demand for targeted therapies that can address the specific needs of patients with varied hormonal imbalances. Innovative drug delivery systems are being developed, including advanced formulations that enhance patient compliance and minimize side effects. The rising interest in personalized medicine creates an opportunity for Pegvisomant to be explored in clinical settings beyond its traditional indications, potentially expanding its application in treating other endocrine disorders. Furthermore, collaborations with research institutions and healthcare providers can lead to clinical trials that may unveil new therapeutic potentials for Pegvisomant, positioning it favorably within the competitive landscape.

Additionally, the growing trend of e-health services and telemedicine creates new avenues for patient engagement and drug distribution. Online pharmacies and telemedicine platforms are becoming increasingly popular, allowing patients to access Pegvisomant more conveniently and confidentially. This trend aligns with the need for enhanced patient adherence to treatment regimens, as it removes barriers related to physical access to healthcare facilities. As the healthcare landscape evolves, the Pegvisomant market must adapt to these changes, embracing digital channels and patient-centered approaches to capitalize on the growing opportunities that this innovative medication offers.

Threats

While the Pegvisomant market exhibits promising growth, it also faces several threats that could hinder its progression. One of the primary concerns is the potential for competition from alternative therapies and newer medications that may emerge in the market. As research in endocrinology advances, other drugs that can effectively manage hormonal disorders might be introduced, capturing market share from Pegvisomant. Moreover, the high costs associated with Pegvisomant treatments could deter some patients from seeking therapy, particularly in regions where healthcare reimbursement is limited. This economic barrier could result in slower market penetration and reduced patient adherence, hampering overall growth.

Another significant threat is the ongoing regulatory scrutiny that pharmaceutical companies face. The healthcare landscape is constantly evolving, and regulatory bodies are becoming more stringent regarding drug approvals, manufacturing practices, and marketing strategies. This paradigm shift could lead to increased costs and delays in bringing Pegvisomant to market, affecting supply chains and product availability. Furthermore, the emergence of counterfeit medications poses a serious risk, as patients may inadvertently turn to less reliable sources for their medications, compromising their health outcomes. Addressing these threats requires continuous innovation, strategic planning, and stringent quality assurance measures to ensure the sustained success of the Pegvisomant market.

Competitor Outlook

• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Sandoz International GmbH
• Horizon Therapeutics plc
• Sun Pharmaceutical Industries Ltd.
• Endo International plc
• Ipsen S.A.
• Recordati S.p.A.
• Aceto Corporation

The competitive landscape of the Pegvisomant market features a diverse set of players ranging from multinational pharmaceutical giants to specialized biotechnology firms, all vying for market share in treating hormonal disorders. Major companies such as Pfizer, Novartis, and Amgen are recognized leaders, given their vast resources and established brands. These companies are actively engaged in research and clinical trials, seeking to innovate and enhance their product lines to better cater to the needs of patients suffering from endocrine disorders. Their focus on R&D, coupled with strategic collaborations and partnerships, positions them well to capitalize on the growing demand for Pegvisomant and similar therapies.

Moreover, companies like Merck and Roche, with their extensive experience in the biotechnology space, are continually evolving their product portfolios to stay ahead of emerging market trends. The emphasis on personalized medicine is particularly evident, as firms are increasingly exploring combination therapies and novel delivery methods that improve patient outcomes. As the market becomes more competitive, these companies are also investing in direct-to-consumer marketing strategies and patient education initiatives to raise awareness and drive adoption of Pegvisomant therapies.

Furthermore, several emerging players are making inroads into the Pegvisomant market, focusing on niche segments or innovative formulations. For instance, firms like Horizon Therapeutics and Ipsen are recognized for their targeted approaches and commitment to addressing unmet medical needs within the hormonal disorder space. These smaller companies often bring agility and creativity in their product development processes, contributing to a dynamic and competitive environment. As the landscape continues to evolve, the interplay between established leaders and emerging innovators will shape the future of Pegvisomant therapy, ultimately benefiting patients and healthcare providers alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Ipsen S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Recordati S.p.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Aceto Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Endo International plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Horizon Therapeutics plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim GmbH
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sandoz International GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Pegvisomant Market, By Application
    • 6.1.1 Acromegaly
    • 6.1.2 Neuroendocrine Tumors
    • 6.1.3 Other Hormonal Disorders
    • 6.1.4 Research
  • 6.2 Pegvisomant Market, By Product Type
    • 6.2.1 Injection
    • 6.2.2 Tablet
    • 6.2.3 Capsule
    • 6.2.4 Liquid
    • 6.2.5 Powder
  • 6.3 Pegvisomant Market, By Ingredient Type
    • 6.3.1 Pegvisomant
  • 6.4 Pegvisomant Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Research Institutes

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Pegvisomant Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Pegvisomant market is categorized based on

By Product Type

• Injection
• Tablet
• Capsule
• Liquid
• Powder

By Application

• Acromegaly
• Neuroendocrine Tumors
• Other Hormonal Disorders
• Research

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Research Institutes

By Ingredient Type

• Pegvisomant

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Merck & Co., Inc.
• Roche Holding AG
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Sandoz International GmbH
• Horizon Therapeutics plc
• Sun Pharmaceutical Industries Ltd.
• Endo International plc
• Ipsen S.A.
• Recordati S.p.A.
• Aceto Corporation